NOUVELLLES AVANCEES TECHNO MEDICALES : revenue, balance sheet and financial ratios

NOUVELLLES AVANCEES TECHNO MEDICALES is a French company founded 28 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in MARIGNANE (13700), this company of category PME shows in 2022 a revenue of 1.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - NOUVELLLES AVANCEES TECHNO MEDICALES (SIREN 414498329)
Indicator 2022 2021 2020 2019 2018 2017 2016
Revenue 1 531 375 € 1 144 828 € 1 072 006 € 1 170 297 € 1 153 002 € 1 535 033 € 1 116 719 €
Net income 171 145 € 63 662 € -41 959 € 28 049 € 34 817 € 93 860 € 39 482 €
EBITDA 239 766 € 74 751 € -38 881 € 48 536 € 54 675 € 130 718 € 70 128 €
Net margin 11.2% 5.6% -3.9% 2.4% 3.0% 6.1% 3.5%

Revenue and income statement

In 2022, NOUVELLLES AVANCEES TECHNO MEDICALES achieves revenue of 1.5 M€. Over the period 2016-2022, the company shows strong growth with a CAGR (compound annual growth rate) of +5.4%. Vs 2021, growth of +34% (1.1 M€ -> 1.5 M€). After deducting consumption (0 €), gross margin stands at 1.5 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 240 k€, representing 15.7% of revenue. Positive scissor effect: EBITDA margin improves by +9.1 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 171 k€, i.e. 11.2% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2022) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

1 531 375 €

Gross margin (2022) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

1 531 375 €

EBITDA (2022) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

239 766 €

EBIT (2022) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

222 680 €

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

171 145 €

EBITDA margin (2022) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

15.7%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 11%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 12.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

11.357%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

52.112%

Cash flow / Revenue (2022) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

12.339%

Repayment capacity (2022) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.137

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

12.2%

Solvency indicators evolution
NOUVELLLES AVANCEES TECHNO MEDICALES

Sector positioning

Debt ratio
11.36 2022
2020
2021
2022
Q1: 0.04
Med: 14.14
Q3: 118.39
Good -30 pts over 3 years

In 2022, the debt ratio of NOUVELLLES AVANCEES TECHN... (11.36) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
52.11% 2022
2020
2021
2022
Q1: 18.05%
Med: 62.02%
Q3: 91.75%
Average +19 pts over 3 years

In 2022, the financial autonomy of NOUVELLLES AVANCEES TECHN... (52.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.14 years 2022
2020
2021
2022
Q1: -0.0 years
Med: 0.04 years
Q3: 3.93 years
Average +26 pts over 3 years

In 2022, the repayment capacity of NOUVELLLES AVANCEES TECHN... (0.14) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 199.37. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.1x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

199.368

Interest coverage (2022) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.064

Liquidity indicators evolution
NOUVELLLES AVANCEES TECHNO MEDICALES

Sector positioning

Liquidity ratio
199.37 2022
2020
2021
2022
Q1: 118.61
Med: 637.87
Q3: 4243.78
Average -6 pts over 3 years

In 2022, the liquidity ratio of NOUVELLLES AVANCEES TECHN... (199.37) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
0.06x 2022
2020
2021
2022
Q1: -75.2x
Med: -1.06x
Q3: 0.0x
Excellent +26 pts over 3 years

In 2022, the interest coverage of NOUVELLLES AVANCEES TECHN... (0.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 6 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 20 days. Favorable situation: supplier credit is longer than customer credit by 14 days. WCR is negative (-21 days): operations structurally generate cash. Notable WCR improvement over the period (-865%), freeing up cash.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-90 994 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

6 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

20 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2022) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-21 j

WCR and payment terms evolution
NOUVELLLES AVANCEES TECHNO MEDICALES

Positioning of NOUVELLLES AVANCEES TECHNO MEDICALES in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (23 transactions). This range of 533 028€ to 2 764 303€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2022
Indicative
533k€ 1382k€ 2764k€
1 382 757 € Range: 533 028€ - 2 764 303€
NAF 5 année 2022

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 23 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare NOUVELLLES AVANCEES TECHNO MEDICALES with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about NOUVELLLES AVANCEES TECHNO MEDICALES

What is the revenue of NOUVELLLES AVANCEES TECHNO MEDICALES ?

The revenue of NOUVELLLES AVANCEES TECHNO MEDICALES in 2022 is 1.5 M€.

Is NOUVELLLES AVANCEES TECHNO MEDICALES profitable?

Yes, NOUVELLLES AVANCEES TECHNO MEDICALES generated a net profit of 171 k€ in 2022.

Where is the headquarters of NOUVELLLES AVANCEES TECHNO MEDICALES ?

The headquarters of NOUVELLLES AVANCEES TECHNO MEDICALES is located in MARIGNANE (13700), in the department Bouches-du-Rhone.

Where to find the tax return of NOUVELLLES AVANCEES TECHNO MEDICALES ?

The tax return of NOUVELLLES AVANCEES TECHNO MEDICALES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does NOUVELLLES AVANCEES TECHNO MEDICALES operate?

NOUVELLLES AVANCEES TECHNO MEDICALES operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.